• C. D. ShermanJr.
Part of the UICC International Union Against Cancer book series (UICCI)


Melanoma is particularly important to study because:
  1. 1.

    It is rapidly increasing in incidence over the world. In the USA, the incidence has doubled every 15 years since 1930 to the current rate of 7 per 100,000. In the clear sunny skies of the US southwest, the incidence is 25 per 100,000 which is about the same as in Queensland, Australia.

  2. 2.

    It is quite clear that early diagnosis results in markedly increased cure rates.

  3. 3.

    It illustrates the value of both public and professional education, which in Queensland has resulted in cure rates of over 80%.



Dysplastic Nevus Active Specific Immunotherapy Superficial Spreading Melanoma Acrallentiginous Melanoma Isolation Perfusion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Further Reading

  1. Greene MH, Clark WH, Tucker MA, Elder DE, Kraemer KH, Guerry D, Witmer KW, Thompson J, Matozzo I, Frazer MC (1985) Acquired precursors of cutaneous malignant melanoma. The familial dysplastic nevus syndrome. New Engl J Med 213: 91–97CrossRefGoogle Scholar
  2. Legha SS (1989) Current therapy for malignant melanoma. Semin Oncol 16 [Suppl l]: 34–44PubMedGoogle Scholar
  3. Mitchell MS, Kan-Mitchell J, Kempf RA, Harel W, Shau H, Lind S (1988) Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 48: 5883–5893PubMedGoogle Scholar
  4. Overett TK, Shiu MH (1985) Surgical treatment of distant metastatic melanoma: indications and results. Cancer 56: 1222–1230PubMedCrossRefGoogle Scholar
  5. Rosenberg RA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) Progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. New Engl J Med 316: 879–905CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1982

Authors and Affiliations

  • C. D. ShermanJr.

There are no affiliations available

Personalised recommendations